Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
P/E ratio for Senseonics Holdings, Inc. (SENS)
P/E ratio as of 2023: -5.36
According to Senseonics Holdings, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.36. At the end of 2022 the company had a P/E ratio of 3.39.
P/E ratio history for Senseonics Holdings, Inc. from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -5.36 |
| 2022 | 3.39 |
| 2021 | -3.55 |
| 2020 | -1.04 |
| 2019 | -1.37 |
| 2018 | -4.34 |
| 2017 | -5.22 |
| 2016 | -5.42 |
| 2015 | -9.96 |
| 2014 | -0.33 |
| 2013 | -0.13 |